From the Research
Ticagrelor can be safely used in patients with G6PD deficiency, as it does not pose a significant risk for hemolysis in these patients. The provided evidence does not specifically mention ticagrelor as a medication that can trigger hemolytic anemia in G6PD-deficient individuals 1, 2, 3, 4, 5. In fact, the most recent and highest quality study, which is a real-world study published in 2024, found that several medications previously suspected to carry risks for hemolysis in G6PD-deficient patients have been prescribed safely to these patients, providing reassurance to patients, prescribers, and regulators 1.
Key Points to Consider
- Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation without undergoing metabolic activation that could stress red blood cells in G6PD-deficient patients.
- The standard dosing for ticagrelor is typically a 180 mg loading dose followed by 90 mg twice daily for acute coronary syndrome or 60 mg twice daily for long-term therapy after myocardial infarction.
- Patients should take ticagrelor with aspirin (usually 75-100 mg daily) unless specifically contraindicated.
- While ticagrelor is safe regarding G6PD status, patients should still be monitored for its common side effects, including dyspnea, bleeding risk, and potential drug interactions, particularly with strong CYP3A inhibitors or inducers.
Safety Profile
The safety profile of ticagrelor regarding G6PD deficiency gives it an advantage over some other antiplatelet medications when treating patients with this genetic condition. However, it is essential to note that the provided evidence does not directly address the safety of ticagrelor in G6PD-deficient patients, but rather provides a general overview of medications that can trigger hemolytic anemia in these individuals. Therefore, the use of ticagrelor in patients with G6PD deficiency should be based on the individual patient's needs and medical history, and patients should be closely monitored for any potential adverse effects.